[Skip to Content]
[Skip to Content Landing]
June 1952

N-BENZYL-β-CHLOROPROPIONAMIDE (HIBICON®)A New Approach to Anticonvulsant Therapy

Author Affiliations


From the Department of Neurology, University of Tennessee College of Medicine. Assistant Professor of Neurology and Instructor in Neurosurgery, University of Tennessee College of Medicine.

AMA Arch NeurPsych. 1952;67(6):815-820. doi:10.1001/archneurpsyc.1952.02320180092011

MODERN neurosurgical techniques have made possible the successful treatment of some patients with epilepsy by cortical excision or resection of the temporal lobe. At present, however, these methods are applicable to only a small percentage of the total number of patients with chronic convulsive disorders (Penfield and Erickson,1 Penfield and Steelman,2 Walker,3 Morris4). We must, therefore, continue to treat most patients with chronic epilepsy with anticonvulsant drugs, supplemented by psychotherapy and occupational rehabilitation.

Anticonvulsant medication also has its limitations as a method of treatment. Walker3 has estimated that anticonvulsant drugs will eliminate the attacks in about one-half the cases of chronic epilepsy and greatly decrease seizures in 25% more. It is in the resistant 25% that surgical treatment may be most justifiably considered, but even this method will not afford relief in a satisfactory number of cases at the present time (Penfield and Steelman2